Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020)
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426068924?dgcid=rss_sd_all
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426068924?dgcid=rss_sd_all
“Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).” Annals of Oncology.
@article{article36107,
title = {Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50\%: The PERSEE randomized phase III trial (GFPC 01-2020)},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426068924?dgcid=rss_sd_all}
}